Prostate Cancer

An expert in prostate cancer comments on emerging agents and combinations in the pipeline for the treatment of mCRPC.

Scott T. Tagawa, MD, FACP, shares his thoughts on remaining questions for imaging and PSMA-targeted therapy for mCRPC.

Dr Scott T. Tagawa discusses common adverse events associated with 177Lu-PSMA-617 in patients with mCRPC and how to appropriately manage them.

A prostate cancer expert considers clinical implications from the phase 3 VISION study, including the potential role of 177Lu-PSMA-617 therapy for patients with mCRPC.

Scott T. Tagawa, MD, FACP, reviews the phase 3 VISION trial evaluating the use of 177Lu-PSMA-617 therapy in patients with mCRPC.

An expert in prostate cancer reviews available options for the treatment of mCRPC and considerations for selecting the optimal therapy.

Dr Scott T. Tagawa reviews traditional imaging techniques and advances in imaging used in clinical practice for prostate cancer.

Scott T. Tagawa, MD, FACP, discusses the heterogeneity and features of prostate cancer and provides insight on biomarker testing.

Tomasz M. Beer, MD, FACP, shares unmet needs and clinical pearls for the management of patients with mCRPC.

An expert in prostate cancer comments on selecting the optimal systemic therapy for metastatic castration-resistant prostate cancer (mCRPC) treatment.

Tomasz M. Beer, MD, FACP, shares his personal experience using darolutamide for patients with CRPC and discusses his approach to patient selection of the drug in the metastatic setting.

Neeraj Agarwal, MD, spoke with Targeted Oncology about the success of the TITAN and SPARTAN studies as well as its use in real-world prostate cancer populations.

Dr Tomasz M. Beer reviews the use of darolutamide for nonmetastatic CRPC as seen in the ARAMIS trial and metastatic CRPC as seen in the ODENZA trial.

Prostate cancer expert Tomasz M. Beer, MD, FACP, provides insight on the use of molecular and biomarker testing for a patient with mCRPC.

Dr Tomasz M. Beer comments on approaching first-line therapy for a patient with metastatic castration-resistant prostate cancer (mCRPC).

An expert in prostate cancer discusses the typical follow-up and monitoring for a patient with metastatic CRPC.

Tomasz M. Beer, MD, FACP, presents the case of a 62-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and shares his initial impressions.

An expert discusses the future of metastatic castrate-resistant prostate cancer management.

Karim Fizazi, MD, PhD, reviews darolutamide data in prostate cancer, including data from phase II clinical trial, ODENZA.

A key opinion leader discusses impact of ADTs on brain and cognitive function in men with prostate cancer.

Dr. Karim Fizazi describes the use of next generation androgen receptor inhibitors in treatment of metastatic castrate-resistant prostate cancer.

An oncologist explains treatment selection and the systemic therapy options available for patients with metastatic castrate-resistant prostate cancer.

Karim Fizazi, MD, PhD, provides an overview of advances in treatment of metastatic castrate-resistant prostate cancer.

After 8 months on enzalutamide, a patient with castration-resistant prostate cancer had a PSA level of 60.7 ng/mL. The abdominal/pelvic CT showed enlargement of known pelvic lymph nodes, and a bone scan showed progressive disease.

During a virtual live event with other physicians, Sandy Srinivas, MD, reviewed data for 3 antiandrogens used for patients with nonmetastatic castration-resistant prostate cancer, including apalutamide, darolutamide, and enzalutamide.

A 75-year-old man presented with intermittent right hip pain. The case was discussed between of physicians and moderated by Nauman Moazzam, MD.

Alicia K. Morgans, MD, PhD, an associate professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Feinberg School of Medicine, gives an overview of androgen receptor therapy in men with non-metastatic castration-resistant prostate cancer.

Dr. Morgans discusses unmet needs and importance of including multidisciplinary teams when treating patients with mCRPC.

A review of the data from phase 3 randomized Phase 3 Study of 177Lu-PSMA-617 or best supportive/standard of care, VISION, in the treatment of patients with progressive PSMA-positive mCRPC and Dr. Morgans’ experience with 177Lu-PSMA-617.

Dr. Morgans talks about available second-line treatment options for patients with mCRPC and considerations when choosing second and subsequent-line treatment options.